Cargando…

Targeting SHP-1-STAT3 signaling: A promising therapeutic approach for the treatment of cholangiocarcinoma

Sorafenib is a multiple kinase inhibitor which targets Raf kinases, VEGFR, and PDGFR and is approved for the treatment of hepatocellular carcinoma (HCC). Previously, we found that p-STAT3 is a major target of SC-43, a sorafenib derivative. In this study, we report that SC-43-induced apoptosis in cho...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, Ming-Hung, Chen, Li-Ju, Chen, Yen-Lin, Tsai, Ming-Shen, Shiau, Chung-Wai, Chao, Tzu-I, Liu, Chun-Yu, Kao, Jia-Horng, Chen, Kuen-Feng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5630313/ https://www.ncbi.nlm.nih.gov/pubmed/29029413 http://dx.doi.org/10.18632/oncotarget.17779

Ejemplares similares

Pharmacological Targeting SHP-1-STAT3 Signaling Is a Promising Therapeutic Approach for the Treatment of Colorectal Cancer()()
por: Fan, Li-Ching, et al.
Publicado: (2015)

Alteration of SHP-1/p-STAT3 Signaling: A Potential Target for Anticancer Therapy
por: Huang, Tzu-Ting, et al.
Publicado: (2017)

Novel sorafenib analogues induce apoptosis through SHP-1 dependent STAT3 inactivation in human breast cancer cells
por: Liu, Chun-Yu, et al.
Publicado: (2013)

Erratum to: Novel sorafenib analogues induce apoptosis through SHP-1 dependent STAT3 inactivation in human breast cancer cells
por: Liu, Chun-Yu, et al.
Publicado: (2017)

Novel imidazopyridine suppresses STAT3 activation by targeting SHP-1
por: Su, Jung-Chen, et al.
Publicado: (2018)

Sorafenib analogue SC‐60 induces apoptosis through the SHP‐1/STAT3 pathway and enhances docetaxel cytotoxicity in triple‐negative breast cancer cells
por: Liu, Chun‐Yu, et al.
Publicado: (2017)

The tyrosine kinase inhibitor nintedanib activates SHP-1 and induces apoptosis in triple-negative breast cancer cells
por: Liu, Chun-Yu, et al.
Publicado: (2017)

SHP-1 is a target of regorafenib in colorectal cancer
por: Fan, Li-Ching, et al.
Publicado: (2014)

SC-2001 Overcomes STAT3-mediated Sorafenib Resistance through RFX-1/SHP-1 Activation in Hepatocellular Carcinoma()()
por: Su, Jung-Chen, et al.
Publicado: (2014)

Interfering B cell receptor signaling via SHP-1/p-Lyn axis shows therapeutic potential in diffuse large B-cell lymphoma
por: Chen, Ji-Lin, et al.
Publicado: (2022)

Disrupting VEGF-A paracrine and autocrine loops by targeting SHP-1 suppresses triple negative breast cancer metastasis
por: Su, Jung-Chen, et al.
Publicado: (2016)

Two novel SHP-1 agonists, SC-43 and SC-78, are more potent than regorafenib in suppressing the in vitro stemness of human colorectal cancer cells
por: Chung, Shin-Yi, et al.
Publicado: (2018)

Hepatectomy or/with Metastatectomy for Recurrent Intrahepatic Cholangiocarcinoma: Of Promise for Selected Patients
por: Tsai, Chun-Yi, et al.
Publicado: (2022)

RFX1–dependent activation of SHP-1 induces autophagy by a novel obatoclax derivative in hepatocellular carcinoma cells
por: Su, Jung-Chen, et al.
Publicado: (2014)

Identification of SPHK1 as a therapeutic target and marker of poor prognosis in cholangiocarcinoma
por: Chen, Ming-Huang, et al.
Publicado: (2015)

SHP-1/STAT3-Signaling-Axis-Regulated Coupling between BECN1 and SLC7A11 Contributes to Sorafenib-Induced Ferroptosis in Hepatocellular Carcinoma
por: Huang, Chao-Yuan, et al.
Publicado: (2022)

Reappraisal of the Therapeutic Role of Celecoxib in Cholangiocarcinoma
por: Yeh, Chun-Nan, et al.
Publicado: (2013)

Globo H Is a Promising Theranostic Marker for Intrahepatic Cholangiocarcinoma
por: Hung, Tsai‐Hsien, et al.
Publicado: (2021)

Palbociclib induces activation of AMPK and inhibits hepatocellular carcinoma in a CDK4/6‐independent manner
por: Hsieh, Feng‐Shu, et al.
Publicado: (2017)

Risk of cholangiocarcinoma in patients undergoing therapeutic endoscopic retrograde cholangiopancreatography or cholecystectomy: A population based study
por: Wang, Chi-Chih, et al.
Publicado: (2019)

Inhibition of STAT3 in gastric cancer: role of pantoprazole as SHP-1 inducer
por: Koh, Jin Sung, et al.
Publicado: (2018)

SH2 domain-containing phosphatase 1 regulates pyruvate kinase M2 in hepatocellular carcinoma
por: Tai, Wei-Tien, et al.
Publicado: (2016)

Dovitinib Triggers Apoptosis and Autophagic Cell Death by Targeting SHP-1/p-STAT3 Signaling in Human Breast Cancers
por: Chiu, Yi-Han, et al.
Publicado: (2019)

Lipocalin 2 (LCN2) is a promising target for cholangiocarcinoma treatment and bile LCN2 level is a potential cholangiocarcinoma diagnostic marker
por: Chiang, Kun-Chun, et al.
Publicado: (2016)

Shp2 Inhibits Proliferation of Esophageal Squamous Cell Cancer via Dephosphorylation of Stat3
por: Qi, Chen, et al.
Publicado: (2017)

Src-homology protein tyrosine phosphatase-1 agonist, SC-43, reduces liver fibrosis
por: Su, Tung-Hung, et al.
Publicado: (2017)

CIP2A is a target of bortezomib in human triple negative breast cancer cells
por: Tseng, Ling-Ming, et al.
Publicado: (2012)

Protein tyrosine phosphatase 1B targets PITX1/p120RasGAP thus showing therapeutic potential in colorectal carcinoma
por: Teng, Hao-Wei, et al.
Publicado: (2016)

Corrigendum: Protein tyrosine phosphatase 1B targets PITX1/p120RasGAP thus showing therapeutic potential in colorectal carcinoma
por: Teng, Hao-Wei, et al.
Publicado: (2017)

Biomechanical analysis of different dynamic sitting techniques: an exploratory study
por: Li, Chun-Ting, et al.
Publicado: (2019)

Association Between Cholangiocarcinoma and Proton Pump Inhibitors Use: A Nested Case-Control Study
por: Peng, Yen-Chun, et al.
Publicado: (2018)

Luteolin selectively kills STAT3 highly activated gastric cancer cells through enhancing the binding of STAT3 to SHP-1
por: Song, Shiyu, et al.
Publicado: (2017)

Protein Tyrosine Phosphatases, TC-PTP, SHP1, and SHP2, Cooperate in Rapid Dephosphorylation of Stat3 in Keratinocytes Following UVB Irradiation
por: Kim, Dae Joon, et al.
Publicado: (2010)

Peritumoral SPARC expression and patient outcome with resectable intrahepatic cholangiocarcinoma
por: Cheng, Chi-Tung, et al.
Publicado: (2015)

Selective inhibition of leukemia-associated SHP2(E69K) mutant by the allosteric SHP2 inhibitor SHP099
por: Sun, X, et al.
Publicado: (2018)

Chemopreventive and chemotherapeutic effects of dietary supplementation of vitamin D on cholangiocarcinoma in a Chemical-Induced animal model
por: Chiang, Kun-Chun, et al.
Publicado: (2014)

Correction: Luteolin selectively kills STAT3 highly activated gastric cancer cells through enhancing the binding of STAT3 to SHP-1
por: Song, Shiyu, et al.
Publicado: (2018)

Abnormal repression of SHP-1, SHP-2 and SOCS-1 transcription sustains the activation of the JAK/STAT3 pathway and the progression of the disease in multiple myeloma
por: Beldi-Ferchiou, Asma, et al.
Publicado: (2017)

Osteosarcoma cell proliferation suppression via SHP-2-mediated inactivation of the JAK/STAT3 pathway by tubocapsenolide A
por: Zhu, Dongrong, et al.
Publicado: (2021)

SHP2 phosphatase as a novel therapeutic target for melanoma treatment
por: Zhang, Ruo-Yu, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_dc8vtja4u442ripjov6i7nhm4q